{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:03:33Z","timestamp":1788919413755,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,10,21]],"date-time":"2011-10-21T00:00:00Z","timestamp":1319155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,10,21]],"date-time":"2011-10-21T00:00:00Z","timestamp":1319155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1038\/leu.2011.297","type":"journal-article","created":{"date-parts":[[2011,10,21]],"date-time":"2011-10-21T08:55:05Z","timestamp":1319187305000},"page":"1046-1052","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma"],"prefix":"10.1038","volume":"26","author":[{"given":"S M","family":"Ansell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P J","family":"Kurtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P A","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G S","family":"Nowakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D A","family":"Nikcevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G D","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D M","family":"Grote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S C","family":"Ziesmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P T","family":"Silberstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Erlichman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T E","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,10,21]]},"reference":[{"key":"BFleu2011297_CR1","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1200\/JCO.2001.19.3.720","volume":"19","author":"SM Ansell","year":"2001","unstructured":"Ansell SM, Stenson M, Habermann TM, Jelinek DF, Witzig TE . CD4+ T-cell immune response to large B- cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol 2001; 19: 720\u2013726.","journal-title":"J Clin Oncol"},{"key":"BFleu2011297_CR2","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1182\/blood-2007-03-082578","volume":"110","author":"ZZ Yang","year":"2007","unstructured":"Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM . CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25T cells. Blood 2007; 110: 2537\u20132544.","journal-title":"Blood"},{"key":"BFleu2011297_CR3","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.1158\/0008-5472.CAN-09-0266","volume":"69","author":"ZZ Yang","year":"2009","unstructured":"Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM . Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res 2009; 69: 5522\u20135530.","journal-title":"Cancer Res"},{"key":"BFleu2011297_CR4","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1182\/blood-2005-08-3376","volume":"107","author":"ZZ Yang","year":"2006","unstructured":"Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM . Intratumoral CD4+CD25+ regulatory T-cell- mediated suppression of infiltrating CD4+ T-cells in B-cell non-Hodgkin lymphoma. Blood 2006; 107: 3639\u20133646.","journal-title":"Blood"},{"key":"BFleu2011297_CR5","doi-asserted-by":"publisher","first-page":"10145","DOI":"10.1158\/0008-5472.CAN-06-1822","volume":"66","author":"ZZ Yang","year":"2006","unstructured":"Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM . Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res 2006; 66: 10145\u201310152.","journal-title":"Cancer Res"},{"key":"BFleu2011297_CR6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s002620050016","volume":"48","author":"D Shan","year":"2000","unstructured":"Shan D, Ledbetter JA, Press OW . Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000; 48: 673\u2013683.","journal-title":"Cancer Immunol Immunother"},{"key":"BFleu2011297_CR7","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900.012k14_3900_3908","volume":"95","author":"J Golay","year":"2000","unstructured":"Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900\u20133908.","journal-title":"Blood"},{"key":"BFleu2011297_CR8","first-page":"3051","volume":"58","author":"D Wurflein","year":"1998","unstructured":"Wurflein D, Dechant M, Stockmeyer B, Tutt AL, Hu P, Repp R et al. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells. Cancer Res 1998; 58: 3051\u20133058.","journal-title":"Cancer Res"},{"key":"BFleu2011297_CR9","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","volume":"20","author":"JD Hainsworth","year":"2002","unstructured":"Hainsworth JD, Litchy S, Burris III HA, Scullin Jr DC, Corso SW, Yardley DA et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol 2002; 20: 4261\u20134267.","journal-title":"J Clin Oncol"},{"key":"BFleu2011297_CR10","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","volume":"23","author":"JD Hainsworth","year":"2005","unstructured":"Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA . Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma\u2013a randomized phase II trial of the Minnie Pearl Cancer Res Network. J Clin Oncol 2005; 23: 1088\u20131095.","journal-title":"J Clin Oncol"},{"key":"BFleu2011297_CR11","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","volume":"28","author":"G Martinelli","year":"2010","unstructured":"Martinelli G, Schmitz SF, Utiger U, Cerny T, Hess U, Bassi S et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98. J Clin Oncol 2010; 28: 4480\u20134484.","journal-title":"J Clin Oncol"},{"key":"BFleu2011297_CR12","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1200\/JCO.2005.12.052","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE, Vukov AM, Habermann TM, Geyer S, Kurtin PJ, Friedenberg WR et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol. 2005; 23: 1103\u20131108.","journal-title":"J Clin Oncol."},{"key":"BFleu2011297_CR13","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1200\/JCO.2004.03.071","volume":"22","author":"NH Dang","year":"2004","unstructured":"Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D et al. Phase II study of denileukin diftitox for relapsed\/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 4095\u20134102.","journal-title":"J Clin Oncol"},{"key":"BFleu2011297_CR14","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/j.1365-2141.2007.06684.x","volume":"138","author":"NH Dang","year":"2007","unstructured":"Dang NH, Fayad L, McLaughlin P, Romaguara JE, Hagemeister F, Goy A et al. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed\/refractory B-cell non-Hodgkin lymphoma. Br J Haematol 2007; 138: 502\u2013505.","journal-title":"Br J Haematol"},{"key":"BFleu2011297_CR15","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244\u20131253.","journal-title":"J Clin Oncol"},{"key":"BFleu2011297_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0197-2456(00)00115-X","volume":"22","author":"DJ Sargent","year":"2001","unstructured":"Sargent DJ, Chan V, Goldberg RM . A three-outcome design for phase II clinical trials. Control Clin Trials 2001; 22: 117\u2013125.","journal-title":"Control Clin Trials"},{"key":"BFleu2011297_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan E, Meier P . Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457\u2013481.","journal-title":"J Am Stat Assoc"},{"key":"BFleu2011297_CR18","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258\u20131265.","journal-title":"Blood"},{"key":"BFleu2011297_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nri821","volume":"2","author":"EM Shevach","year":"2002","unstructured":"Shevach EM . CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2: 389\u2013400.","journal-title":"Nat Rev Immunol"},{"key":"BFleu2011297_CR20","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1517\/14712598.2.8.827","volume":"2","author":"MA Morse","year":"2002","unstructured":"Morse MA, Clay TM, Mosca P, Lyerly HK . Immunoregulatory T cells in cancer immunotherapy. Expert Opin Biol Ther 2002; 2: 827\u2013834.","journal-title":"Expert Opin Biol Ther"},{"key":"BFleu2011297_CR21","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.4049\/jimmunol.169.5.2756","volume":"169","author":"UK Liyanage","year":"2002","unstructured":"Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169: 2756\u20132761.","journal-title":"J Immunol"},{"key":"BFleu2011297_CR22","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.4049\/jimmunol.168.9.4272","volume":"168","author":"EY Woo","year":"2002","unstructured":"Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002; 168: 4272\u20134276.","journal-title":"J Immunol"},{"key":"BFleu2011297_CR23","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.4049\/jimmunol.181.5.3285","volume":"181","author":"KB Vang","year":"2008","unstructured":"Vang KB, Yang J, Mahmud SA, Burchill MA, Vegoe AL, Farrar MA . IL-2, -7, and -15, but not thymic stromal lymphopoeitin, redundantly govern CD4+Foxp3+ regulatory T cell development. J Immunol 2008; 181: 3285\u20133290.","journal-title":"J Immunol"},{"key":"BFleu2011297_CR24","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.4049\/jimmunol.173.5.2942","volume":"173","author":"N Sarween","year":"2004","unstructured":"Sarween N, Chodos A, Raykundalia C, Khan M, Abbas AK, Walker LS . CD4+CD25+ cells controlling a pathogenic CD4 response inhibit cytokine differentiation, CXCR-3 expression, and tissue invasion. J Immunol 2004; 173: 2942\u20132951.","journal-title":"J Immunol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2011297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2011297","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2011297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T14:42:48Z","timestamp":1648737768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2011297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,21]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["BFleu2011297"],"URL":"https:\/\/doi.org\/10.1038\/leu.2011.297","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,21]]},"assertion":[{"value":"8 September 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SMA received research funding from Eisai Inc. for this study. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}